DEHP: The Phthalate in Food Packaging and Everyday Products

DEHP is the highest-volume phthalate on earth — roughly 3 million tonnes produced globally per year, making DEHP the single most manufactured phthalate produced per year. It's in food packaging, vinyl flooring, shower curtains, car interiors, cable insulation, and medical devices. MEHPMono(2-ethylhexyl) phthalate — the primary urinary metabolite of DEHP. Detected in 78% of the US population in NHANES biomonitoring., its primary metabolite, has been detected in 78% of the US population had detectable DEHP metabolites in NHANES 1999-2000 biomonitoring of the US population Kato et al. 2004. DEHP is the single member of the phthalate family you're most likely carrying — and this article covers the exposure route nobody outside a hospital thinks about.

DEHP — di(2-ethylhexyl) phthalate, CAS 117-81-7 — is a synthetic ester of phthalic acid that has been the dominant PVC plasticiser since the 1930s. It constitutes 50%+ of all plasticiser production globally — DEHP is to PVC what sugar is to baking of global plasticiser production. Wherever you see flexible PVC — the shower curtain that drapes instead of cracking, the cable that bends instead of snapping, the blood bag that squeezes instead of shattering — DEHP is almost certainly the reason. The molecule isn't chemically bonded to the PVC chain. It sits between the polymer strands like oil between gears, and it migrates out whenever heat, fat, or time gives it the opportunity.

That migration is the exposure route. Hot food in plastic wrap. A stored blood bag leaching DEHP into the blood inside it. A premature infant's IV line delivering plasticiser along with the medication. The chemical was designed to leave the plastic. It does exactly what it was designed to do — and the destinations include your food and your bloodstream.

For most adults, the dominant route is food — specifically food that has been stored, heated, or wrapped in flexible PVC. Five families who switched from their normal diet to fresh food for three days — nothing from cans or plastic packaging — dropped DEHP metabolites by 53-56% geometric mean reduction in urinary DEHP metabolites after 3 days on fresh food, with maximum reductions of 93-96% Rudel et al. 2011. When they went back to their normal food, levels rebounded within days. Three days to drop by half. Three days back to where you started. The body clears DEHP in hours — the exposure is what's constant.

Food is one route. The other one runs along the floor. Vinyl flooring is roughly a quarter DEHP by weight, and the plasticiser migrates out into household dust over years of warmth and foot traffic — a slower drip than the cling film, but a steady one, and children spend their lives at floor level breathing it.

The cleanest evidence on what that does came out of Sweden in 2004. Bornehag and colleagues had built a DBH studyDampness in Buildings and Health — a Swedish prospective birth cohort of 10,852 children in Värmland, established in 2000 to investigate links between the indoor home environment and childhood allergic disease. cohort of 10,852 children in Värmland and were watching for the early signs of asthma and allergic disease. They nested a case-control study inside it: 198 children with persistent allergic symptoms, 202 healthy controls, all aged 3-8. Then they sent investigators into 390 homes to vacuum the dust off the bedroom floors. Of the 346 dust samples that survived lab handling, the children in the highest-exposure quartile of BBzPBenzyl butyl phthalate — a phthalate plasticiser used in vinyl flooring, food packaging, and personal care products. Distinct from DEHP but in the same anti-androgenic family. dust had three times the odds of allergic rhinitis (OR 3.04 95% CI 1.34-6.89, BBzP highest quartile vs lowest, persistent allergic rhinitis in Värmland children, 95% CI 1.34-6.89) and 2.5 times the odds of eczema. The DEHP signal landed on asthma: OR 2.93 95% CI 1.36-6.34, DEHP highest quartile vs lowest, persistent asthma in Värmland children, 95% CI 1.36-6.34 Bornehag et al. 2004. The flooring you walked over as a toddler. The dust you breathed before you could read. A signal large enough to find with 400 children.

This is the part of the DEHP story that most consumer articles don't cover, and it's the part the NTPNational Toxicology Program — a US federal interagency program that evaluates chemicals for potential health effects. flagged with the highest concern. Neonatal intensive care units run on PVC. IV lines, feeding tubes, endotracheal tubes, ECMOExtracorporeal membrane oxygenation — a life-support system that pumps blood through an external oxygenator. Used for critically ill newborns with heart or lung failure. The circuit requires extensive PVC tubing. circuits, blood transfusion bags — all flexible PVC, all containing DEHP, all in continuous contact with fluids that go directly into the bloodstream of a newborn.

Fifty-four neonates across two level III NICUs were enrolled in the first study to measure what that meant. Researchers categorised each infant by device intensity — low, medium, or high — based on how many DEHP-containing products were touching their bodies at any given time. Then they measured urinary MEHP. The gradient was clean: low-exposure infants had a median of 4 ng/mL. High-exposure infants — the ones on ventilators, central lines, multiple IV infusions — had 86 ng/mL median urinary MEHP in high-exposure NICU infants — 5.1 times the low-exposure group, a 5.1× difference Green et al. 2005. A follow-up measuring the oxidative metabolites MEHHP and MEOHP — better biomarkers than MEHP itself, because they cannot be generated by sample contamination — confirmed the pattern at 13-14× the low-exposure levels Weuve et al. 2006.

The NTP-CERHR monograph on DEHP — the foundational governmental risk assessment for this chemical — graduated its concern by exposure level. For adults at typical dietary exposures of 1-30 µg/kg/day: 'minimal concern.' For male infants undergoing intensive medical treatment at exposures up to 6,000 µg/kg/day roughly 200 times the upper end of typical adult dietary exposure: 'serious concern' NTP-CERHR 2006.

A 2021 study put those numbers to the test. Researchers in a French NICU enrolled 104 neonates and measured the plasticiser metabolites in their urine while tracking every medical device connected to each infant — every IV line, every feeding tube, every circuit. For infants on ECMO — the life-support system that pumps a newborn's blood through an external oxygenator and back, through metres of PVC tubing — DEHP exposure exceeded the derived no-effect level by approximately 1,000×. Three orders of magnitude above what toxicologists consider the threshold of concern. The study also detected alternative plasticisers (DINCH, DEHT) in some device categories, confirming that replacements exist and are already entering clinical use Bernard et al. 2021. The most vulnerable patients, receiving the highest doses, through the most direct route, of a chemical rated 'serious concern' by the agency that evaluates it.

Alternatives exist. DEHTDi(2-ethylhexyl) terephthalate — a non-phthalate plasticiser used as a DEHP replacement in medical devices. Structurally similar to DEHP but with a terephthalate backbone rather than a phthalate one., DINCHDiisononyl cyclohexane-1,2-dicarboxylate — a non-phthalate plasticiser developed specifically as a DEHP replacement for sensitive applications including food contact and medical devices., and TOTMTrioctyl trimellitate — a plasticiser used in blood bags and medical tubing as a DEHP alternative. Higher molecular weight reduces migration. are all commercially available non-phthalate plasticisers approved for medical devices. The EU has banned DEHP from medical devices effective July 2030, with authorisation applications required by January 2029. The US FDA recommends labelling and alternatives for high-risk populations — neonates, pregnant women — but has not banned DEHP from medical devices.

DEHP's metabolite MEHP detected in 78% of US adults — a near-universal exposure suppresses testosterone production in fetal Leydig cells by downregulating the upstream steroidogenic machinery — StARSteroidogenic acute regulatory protein — the rate-limiting transport protein that moves cholesterol into the mitochondria, where testosterone synthesis begins., the translocator protein PBR, the cholesterol side-chain cleavage enzyme P450scc, and the nuclear regulators SF-1 and PPARgamma. Transcripts for the testicular descent factor InsL3 dropped in the same Wistar rat fetuses Borch et al. 2006. The mechanism sits upstream of receptor-binding anti-androgens like flutamide: DEHP doesn't block androgen receptors so much as lower how much testosterone reaches them in the first place. Less testosterone produced during the masculinisation programming windowA critical period during fetal development when testosterone directs the formation of male reproductive anatomy. Insufficient testosterone during this window produces measurable changes at birth. means altered development that shows up at birth.

An important nuance carried from the phthalates overview: in the most-cited human study on phthalates and male reproductive development, DEHP's hydrolytic metabolite MEHP showed no significant association with reduced anogenital distance — p = 0.833 Swan et al. 2005. The phthalate metabolites that DID show effects (MBP, MiBP, MEP) came from personal care products, not food packaging.

The Swan 2005 nuance has aged in the way nuances do. When Zarean and colleagues pooled ten studies of prenatal phthalate exposure and male anogenital distanceThe distance from the anus to the genitalia, measured at birth. A sensitive marker of fetal androgen exposure during the masculinisation programming window — shorter AGD in male infants indicates lower prenatal testosterone. in 2019, the picture sharpened. MEHPMono(2-ethylhexyl) phthalate — DEHP's primary urinary metabolite. The biomarker Swan 2005 used; non-significant on its own. alone — the metabolite Swan tested — still didn't reach significance. But summed DEHP metabolites (MEHP plus its oxidative descendants) shortened the anogenital distance on both standard measurement axes — anopenile β = -0.915 (95% CI -1.629, -0.20), anoscrotal β = -0.857 (95% CI -1.455, -0.26) Zarean et al. 2019. The metabolite-by-metabolite null was a measurement-method artefact, not biology.

In 2019, EFSA followed the same logic. The agency set a group TDITolerable Daily Intake — the amount of a chemical that can be ingested daily over a lifetime without appreciable health risk. A group TDI applies to several chemicals jointly, on the basis that they share a common biological target and add up additively in the body. of 50 µg/kg bw/dayexpressed as DEHP equivalents — the same body-weight-adjusted limit applied to four phthalates jointly for DEHP, DBP, BBP, and DINP combined, expressed as DEHP equivalents, on the explicit grounds that all four reduce fetal testosterone through the same anti-androgenic mode of action and add up additively in the body EFSA CEP Panel 2019. The regulators finally treat phthalates the way the body does — additively, never one at a time.

Three REACH instruments stack up on the EU side, and they're worth keeping straight. Annex XVIIThe REACH restriction list — direct prohibitions or limits on the manufacture, use, or marketing of substances. Entry 51 is the phthalate restriction. Entry 51 is the consumer-product restriction — DEHP, DBP, BBP, and DiBP capped at 0.1% individually or in combination across all consumer articles since 7 July 2020 (Regulation 2018/2005). Annex XIVThe REACH authorisation list — substances cannot legally be used after the sunset date without a granted authorisation for a specific use. is the authorisation list — DEHP was added in 2011 by Regulation 143/2011, and after a sequence of sunset extensions the latest application date for medical-device uses now falls on 1 January 2029, with the sunset itself on 1 July 2030 (Regulation 2023/2482). The SVHCSubstance of Very High Concern Candidate List sits upstream of both, identifying substances that warrant restriction; DEHP was first listed in 2008 for reproductive toxicity, and Regulation 2021/2045 added its endocrine-disrupting properties to the Annex XIV entry — bringing previously-exempt uses (medical devices, immediate food packaging) into the authorisation regime.

The EU Medical Device Regulation is a separate animal. Reg 2017/745 Annex I §10.4 has been in force since 26 May 2021 and requires manufacturers to justify and label any DEHP content above 0.1% by weight in invasive or blood-contacting devices — not a ban, but a documentation regime that pushes the alternatives forward by raising the cost of DEHP-containing designs. The US has, for the first time, started catching up. EPA finalised its TSCA risk evaluation for DEHP on 6 January 2026 (91 FR 373 Federal Register publication of the TSCA Final Risk Evaluation bundling BBP, DBP, DCHP, DEHP, and DIBP — January 2026, bundling DEHP with BBP, DBP, DCHP, and DIBP), determining 'unreasonable risk to human health and/or the environment driven by specific conditions of use.' Under TSCA, that finding mandates a risk-management rule. Twenty-eight years after the EU first restricted DEHP in toys. But it's moving.

The medical alternatives exist because regulators forced them to. DINCHDiisononyl cyclohexane-1,2-dicarboxylate — a non-aromatic plasticiser developed by BASF as a DEHP replacement for sensitive applications. Cleared for medical devices and food contact in the EU. (the saturated cousin of DINP), DEHTDi(2-ethylhexyl) terephthalate — a plasticiser sharing DEHP's molecular weight but with a para benzene ring substitution that markedly reduces anti-androgenic activity in screening assays., and TOTMTrioctyl trimellitate — a higher-molecular-weight plasticiser used in blood bags and medical tubing as a DEHP alternative. Lower migration rates due to molecular weight. are now in routine use in EU paediatric IV sets. The honest reading of the alternatives literature, surveying twenty replacement plasticisers across the human exposure record, calls them 'pseudo-persistent' — present in the population, but with risk ratios under 1 across the assessed endpoints, with the single exception of infant exposure to ESBOepoxidised soybean oil — a non-phthalate plasticiser flagged by Bui et al. 2016 for elevated infant risk ratio Bui et al. 2016. Not perfect. Not a solved problem. But the body of evidence on DINCH and DEHT, after a decade of biomonitoring, is much weaker on the harm side than DEHP's record was at the same point in its lifecycle. The regrettable-substitution case where the regret hasn't materialised — yet.

DEHP clears the body in hours — like all phthalates, the problem is daily re-exposure, not accumulation. What you buy this week determines your level next week. The eso-friendly framework applies directly: the mechanism for harm is established, the evidence is consistent, and glass containers cost about the same.

Go back to the cling film. You pressed it over a bowl of hot food, and it clung — because DEHP made the PVC flexible enough to stretch and stick. The same property that makes it useful in your kitchen makes it mobile: DEHP isn't bonded to the plastic, so it migrates into whatever the plastic touches. Hot food. Household dust. Stored blood. A premature baby's IV fluid.

The NTP rated that last scenario 'serious concern' — the highest level of alarm the agency uses for a non-cancer endpoint. The EU is phasing it out of medical devices through REACH authorisation by July 2030; EPA finalised an unreasonable-risk determination in January 2026 with risk-management rulemaking pending. In your kitchen, the alternative is simpler than either: glass doesn't need a plasticiser, because glass was never rigid PVC in the first place.